| Literature DB >> 30159383 |
Zongyue Zeng1,2, Bo Huang1,2,3, Shifeng Huang2,4, Ruyi Zhang1,2, Shujuan Yan1,2, Xinyi Yu2,4, Yi Shu2,5, Chen Zhao2,4, Jiayan Lei2,4, Wenwen Zhang2,6, Chao Yang2,5, Ke Wu1,2, Ying Wu2,7, Liping An2,8, Xiaojuan Ji2,5, Cheng Gong2,9, Chengfu Yuan2,10, Linghuan Zhang2,5, Wei Liu2,4, Yixiao Feng2,4, Bo Zhang2,8, Zhengyu Dai2,11, Yi Shen2,12, Xi Wang1,2, Wenping Luo2,13, Rex C Haydon2,4, Hue H Luu2,4, Lan Zhou2,4, Russell R Reid2,14, Tong-Chuan He1,2, Xingye Wu2,4.
Abstract
While the human genome is pervasively transcribed, <2% of the human genome is transcribed into protein-coding mRNAs, leaving most of the transcripts as noncoding RNAs, such as microRNAs and long-noncoding RNAs (lncRNAs), which are critical components of epigenetic regulation. lncRNAs are emerging as critical regulators of gene expression and genomic stability. However, it remains largely unknown about how lncRNAs are regulated. Here, we develop a highly sensitive and dynamic reporter that allows us to identify and/or monitor negative modulators of lncRNA transcript levels in a high throughput fashion. Specifically, we engineer a fluorescent fusion protein by fusing three copies of the PEST destruction domain of mouse ornithine decarboxylase (MODC) to the C-terminal end of the codon-optimized bilirubin-inducible fluorescent protein, designated as dBiFP, and show that the dBiFP protein is highly destabilized, compared with the commonly-used eGFP protein. We further demonstrate that the dBiFP signal is effectively down-regulated when the dBiFP and mouse lncRNA H19 chimeric transcript is silenced by mouse H19-specific siRNAs. Therefore, our results strongly suggest that the dBiFP fusion protein may serve as a sensitive and dynamic transcript reporter to monitor the inhibition of lncRNAs by microRNAs, synthetic regulatory RNA molecules, RNA binding proteins, and/or small molecule inhibitors so that novel and efficacious inhibitors targeting the epigenetic circuit can be discovered to treat human diseases such as cancer and other chronic disorders.Entities:
Keywords: BiFP; IncRNA; green fluorescent protein; high throughput screening; noncoding RNA; transcript reporter assay
Year: 2018 PMID: 30159383 PMCID: PMC6110536 DOI: 10.1016/j.gendis.2018.02.001
Source DB: PubMed Journal: Genes Dis ISSN: 2352-3042
Figure 1Fusion proteins of eGFP and Gaussia luciferase (GLuc) with multiple copies of the MODC PEST domain exhibit varied instabilities. (A) Schematic representation of the construction of eGFP-3modc C-terminal fusion and its control eGFP vectors. Both constructs were generated on the basis of our homemade pSEH retroviral vector, yielding pSEH-eGFP and pSEH-eGFP-3modc. LTR, long terminal repeat for MSCV retrovirus; Hygro, hygromycin B resistance gene; hEFH, a hybrid promoter consisting of human EF1α promoter and HIV enhancer; eGFP, enhanced green fluorescent protein; stop, stop codon; 3modc, three copies of the PEST-containing degradation domain of mouse ornithine decarboxylase. (B) The fluorescence signal of the eGFP-3modc fusion after cycloheximide (CHX) treatment. The retroviral vectors were used to make stable cell lines of HCT116 cells after hygromycin selection. The stable lines were seeded at subconfluency and treated with cycloheximide (100 μg/ml). Fluorescence signals were recorded at the indicated time points. Representative images are shown. (C) Quantitative analysis of the fluorescence intensity in the samples prepared in (B). “*” p < 0.05 compared with GFP signal between 0 h and 12 h. (D) Schematic representation of the construction of GLuc-3modc fusion and its control GLuc vectors. Both constructs were retroviral vectors, namely pSEH-GLuc and pSEH-GLuc-3modc. (E). The retroviral vectors were used to make stable HCT116 cell lines, as described in (B). Basal GLuc activity was measured. “**” p < 0.01, compared with non-fusion GLuc control line. (F). GLuc activity retained after CHX treatment. The GLuc and GLuc-3modc stable lines were treated with CHX (100 μg/ml). GLuc activities were measured at the indicated time points. “*p < 0.05, “**”p < 0.01, compared with the GLuc activity at 0 h time point.
Figure 2The construction and expression of codon-optimized bilirubin-inducible fluorescent protein (BiFP). (A) Codon optimization of BiFP. The protein sequence of BiFP (aka, UnaG) () and its crystal structure () were previously described in reference. As the original gene was identified from Japanese eel muscle cells, we humanized the gene; and the codon optimized BiFP and original UnaG coding sequences were compared and shown in (). (B) Effective expression of BiFP in HEK-293 cells. The codon optimized BiFP was subcloned into pSEH vector and transiently transfected into HEK-293 cells. The green fluorescence signal was recorded at the indicated time points. Representative images are shown.
Figure 3Characterization of the degradability of BiFP-modc C-terminal fusion proteins. (A) Schematic representation of destabilized BiFP constructs with zero to three copies of MODC PEST domain at the C-terminus of BiFP. The fusion constructs were generated and cloned in the pSEH retroviral vector, yielding pSEH-BiFP, pSEH-BiFP-modc, pSEH-BiFP-2modc, and pSEH-BiFP-3modc, respectively. (B) BiFP fusion constructs were used for retrovirus packaging and generating stable lines in HCT116 cells after hygromycin selection. Subconfluent stable lines were treated with CHX (100 μg/ml). Fluorescence signals were recorded at the indicated time points. Representative images are shown. (C) Quantitative analysis of the fluorescence signal for the CHX-treated stable lines shown in (B). “*” p < 0.05; “**” p < 0.01, compared with the BiFP signals at 0 h after CHX treatment of respective stable lines.
Figure 4Degradability comparison of the BiFP fusion proteins containing the C-terminal or N-terminal MODC PEST domains. (A) Schematic representation of N-terminal and C-terminal fusion proteins of BiFP. The BiFP-3modc fusion construct is also designated as degradable BiFP or dBiFP. These constructs were generated in pSEH vector, resulting in pSEH-3modc-BiFP, pSEH-BiFP-3modc and pSEH-BiFP. (B) The retroviral vectors were used to generate stable HCT116 lines. Subconfluent stable lines were treated with CHX (100 μg/ml). Fluorescence signals were recorded at the indicated time points. Representative images are shown. (C) Quantitative analysis of the fluorescence signal for the CHX-treated stable lines shown in (B). “*” p < 0.05; “**” p < 0.01, compared with the BiFP signals at 0 h after CHX treatment of respective stable lines.
Figure 5The highly degradable dBiFP as a sensitive transcription reporter of lncRNA H19. (A). Schematic representation of the construction of dBiFP-H19 transcriptional reporter. Mouse lncRNA H19 (mH19) was cloned into the downstream of the stop codon of the dBiFP coding region. It is expected a chimeric transcript of dBiFP-mH19 will be generated, which will be further translated into the highly degradable protein dBiFP. Targeting mH19 by siRNAs, miRNAs, naturally occurring or synthetic modulatory RNAs, or small molecule compounds may lead to a decrease in the chimeric transcript and thus the decrease in BiFP signal. As a proof-of-principle experiment, we use an adenoviral vector expressing mH19-specific siRNAs, AdR-simH19 to knockdown mH19 transcript. (B). Generation of a stable dBiFP-H19 reporter line from HCT116 cells. TqPCR analysis indicates the high expression of mouse H19 in the dBiFP-H19 HCT116 stable line (p < 0.01 compared with that of the control line dBiFP). (C). H19-specific siRNAs effectively down-regulate dBiFP expression in dBiFP-H19 cells. Subconfluent dBiFP and dBiFP-H19 cells were infected with AdR-simH19 or AdRFP. Fluorescence signals were recorded at 0 h and 36 h after infection (). The BiFP fluorescence signal was quantitatively analyzed (). “**”, p < 0.01 compared the AdR-simH19 infection with that of AdRFP infection. (D). TqPCR analysis of mouse H19 in dBiFP-H19 cells upon AdR-simH19 silencing. Subconfluent dBiFP and dBiFP-H19 cells were infected with AdR-simH19 or AdRFP for 36 h. Total RNA was isolated and subjected to RT-PCR analysis. TqPCR assay was done in triplicate. “**” p < 0.01 when compared the expression level of AdR-simH19 infection with that of AdRFP infection.